| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
9 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $162.56, a high estimate of $180.00, and a low estimate of $128.00. This current average reflects an increase of 2.61% from the previous average price target of $158.43.
A comprehensive examination of how financial experts perceive Sarepta Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Kostas Biliouris | BMO Capital | Maintains | Outperform | $170.00 | $170.00 |
| Biren Amin | Piper Sandler | Announces | Overweight | $157.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $142.00 | $157.00 |
| Gil Blum | Needham | Maintains | Buy | $166.00 | $166.00 |
| Uy Ear | Mizuho | Raises | Buy | $179.00 | $145.00 |
| Hartaj Singh | Oppenheimer | Announces | Outperform | $180.00 | - |
| Anupam Rama | JP Morgan | Lowers | Overweight | $175.00 | $177.00 |
| Gil Blum | Needham | Maintains | Buy | $166.00 | $166.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | $128.00 |
For valuable insights into Sarepta Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Sarepta Therapeutics showcased positive performance, achieving a revenue growth rate of 63.1% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.74%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sarepta Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sarepta Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.44.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SRPT
